Mind + Muscle

technical minds + legal muscle


dig deep

Looking Forward: Section 337 Investigations as Big Pharma's New Enforcer

  • 01.26.12
  • Christopher M. Gallo
  • Sterne, Kessler, Goldstein & Fox

In this article, Christopher M. Gallo discusses the increase of generic pharmaceutical competition under the Hatch-Waxman Act and the growing number of innovator companies that are utilizing ITC Section 337 investigations to curb generic competition and maintain market exclusivity. To access the full article, click on the PDF above.

Article originally published in Vol. XXXIV 337  Rep., ITC Trial Law. Ass'n, The Paul J. Luckern Summer Associate Edition 2 (2011).

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.